Abstract A48: Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR,VEGFR,RET) in children, adolescents, and young adults with advanced solid tumors
Keyword(s):
Phase I
◽
2005 ◽
Vol 23
(16_suppl)
◽
pp. 3007-3007
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. 3020-3020
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3008-3008
◽